Background:

PhD student in Virology at the Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, South Africa. My research interests are in understanding levels of primary HIV-1 drug resistant minority variants and their impact on antiretroviral treatment (ART). I would specifically want to determine how drug resistant minority variants detected using next generation sequencing platforms can be used to inform use of antiretroviral drugs in clinical practice, when initiating patients on ART. I am also interested in the use of bioinformatics for large scale data analysis in the field of molecular biology.

Affiliations:

KRISP - KwaZulu-Natal Research and Innovation Sequencing Platform, UKZN, Durban, South Africa.

Department of Virology, National Health Laboratory Service (NHLS), Durban, South Africa (PhD student).

Centre for AIDS Programme of Research (CAPRISA), South Africa (Research fellow).

Letten Foundation, Oslo University, Norway (Research fellow).

Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000–2016: A Pooled Sequence Analysis.
Chimukangara B, Lessells RJ, Rhee S-Y, Giandhari J, Kharsany ABM, Naidoo K, Lewis L, Cawood C, Khanyile D, Ayalew KA, Diallo K, Samuel R, Hunt G, Vandormael A, Stray-Pedersen B, Gordon M, Makadzange T, Kiepiela P, Ramjee G, Ledwaba J, Kalimashe M, Morris L, Parikh UM, Mellors JW, Shafer RW, Katzenstein D, Moodley P, Gupta RK, Pillay D, Karim SSA, de Oliveira T, EClinicalMedicine (Lancet) (2019), DOI:https://doi.org/10.1016/j.eclinm.2019.03.006:.

Moderate to high levels of pre-treatment HIV drug resistance in KwaZulu-Natal Province, South Africa.
Chimukangara B, Kharsany AB, Lessells RJ, Naidoo K, Rhee SY, Manasa J, Gräf T, Lewis L, Cawood C, Khanyile D, Diallo K, Ayalew KA, Shafer R, Hunt G, Pillay D, Abdool SK, de Oliveira T, AIDS Research and Human Retroviruses (2019), https://doi.org/10.1089/AID.2018.0202:.

Recurrent tuberculosis among HIV-coinfected patients: a case series from KwaZulu-Natal.
Naidoo K, Dookie N, Naidoo K, Yende-Zuma N, Chimukangara B, Bhushan A, Govender D, Gengiah S, Padayatchi N, Infect Drug Resist (2018), 11:1413-1421.

Primary HIV-1 Drug Resistant Minority Variants.
Chimukangara B, Samuel R, Naidoo K, de Oliveira T, AIDS Reviews (2017), 19(2):[Epub ahead of print].

HIV drug resistance testing among patients failing second line antiretroviral therapy-Comparison of in-house and commercial sequencing.
Chimukangara B, Varyani B, Shamu T, Mutsvangwa J, Manasa J, White E, Chimbetete C, Luethy R, Katzenstein D, J Virol Methods (2016), pii: S0166-0934(16)30289-0: doi: 10.1016/j.jviromet.2016.11.010.

Clinical, Virologic, Immunologic Outcomes and Emerging HIV Drug Resistance Patterns in Children and Adolescents in Public ART Care in Zimbabwe.
Makadzange AT, Higgins-Biddle M, Chimukangara B, Birri R, Gordon M, Mahlanza T, McHugh G, van Dijk JH, Bwakura-Dangarembizi M, Ndung'u T, Masimirembwa C, Phelps B, Amzel A, Ojikutu BO, Walker BD, Ndhlovu CE, PLoS One (2015), 10(12):DOI: 10.1371/journal.pone.0144057 .

Drug resistance mutations from whole blood proviral DNA among patients on antiretroviral drugs in Zimbabwe.
Chimukangara B, Gwanzura G, Mitchell R, Katzenstein D, Masimirembwa C , Curr HIV Res (2014), 12(5):309-16.